Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

IGC Pharma Q1 2025 GAAP EPS $(0.03), Inline, Sales $272.000K Miss $310.000K Estimate

Author: Benzinga Newsdesk | August 09, 2024 01:48am
IGC Pharma (AMEX:IGC) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 25 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $272.000 thousand which missed the analyst consensus estimate of $310.000 thousand by 12.26 percent. This is a 50.99 percent decrease over sales of $555.000 thousand the same period last year.

Posted In: IGC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist